Communicators

Sydney Australia, 26 November 2024: Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), the Company developing a New Class of Synthetic Anti-Infectives, is pleased to announce the Australian Patent Office has formally granted Patent Family 3 for Recce’s Anti-infectives, expiry 2037.

The Australian Patent claims relating to RECCE® 327 (R327) and RECCE® 529 (R529), most notably:

-          Process for the manufacture of RECCE® Anti-infectives and a copolymer made by the claimed process.

-          Use of R327 or R529 for the treatment of infections

-          Methods of administration of R327 or R529 by oral, injection, inhalation and transdermal dose applications

This is the final of Recce’s wholly owned patents Granted for Family 3 and the final patent to be granted in Australia, with the Company now patent protected in all major pharmaceutical markets globally.

Recce Pharmaceuticals’ Chief Executive Officer, James Graham said: “We are thrilled by the Australian Patent Office’s formal recognition of the ground-breaking potential of Recce’s New Class of Anti-Infectives. The granting of Patent Family 3 solidifies our global intellectual property portfolio, providing protection for R327 and R529 across all major pharmaceutical markets until 2037. This milestone underscores our commitment to addressing critical viral threats with innovative therapies and ensures we are well-positioned to deliver meaningful solutions for patients worldwide.”

This announcement has been approved for release by Recce Pharmaceuticals Board.

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs.

Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE® 435 (R435) as an orally administered therapy for bacterial infections; and RECCE® 529 (R529) for viral infections. Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics.

The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in clinical development for priority pathogens, recognising Recce’s efforts to combat antimicrobial resistance. The FDA granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval. R327 is also included on The Pew Charitable Trusts’ Global New Antibiotics in Development Pipeline as the sole synthetic polymer and sepsis drug candidate in development.

Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce’s anti-infective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies.